Comparative Effectiveness Research and the Environment for Health Care Decision-Making

Now in its fourth year, the National Pharmaceutical Council’s annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making.

WHO DID WE SURVEY?

- Associations 10%
- Government 10%
- Insurers/Health Plans 15%
- Employers 24%
- Researchers/Thought Leaders 35%
- Business Coalitions 26%

THEY SAID CER IS IMPORTANT

- Very Important 59%
- Somewhat Important 35%
- Slightly Important 5%
- Not at All Important 1%

BUT ITS IMPACT ON DECISION-MAKING IS STILL DOWN THE ROAD

- Past Year 16%
- 1 Year 37%
- Next 3 Years 77%
- Next 5 Years 92%

WHICH ORGANIZATIONS PLAY KEY ROLES IN THE CER EFFORT?

- Setting CER Priorities
  - AHRQ (62%)
  - NIH (66%)
  - PCORI (76%)

- Setting CER Standards
  - AHRQ (71%)
  - NIH (55%)
  - PCORI (70%)

- Monitoring Research Funding
  - Industry (60%)
  - NIH (77%)
  - PCORI (76%)

- Conducting CER
  - Industry (65%)
  - Academia (85%)

- Disseminating CER
  - AHRQ (80%)
  - Academia (72%)
  - PCORI (69%)